CLINICAL ROLE -
Enfortumab Vedotin With Pembrolizumab Shows Promise as First-Line Therapy For Those Ineligible for Cisplatin
Enfortumab vedotin in combination with pembrolizumab showed a manageable safety profile and promising progression free survival and overall survival for locally advanced or metastatic urothelial cancer.
Read More